A meta-analysis of temporal changes of response in the placebo arm of surgical randomized controlled trials:an update by Wartolowska, K.A. et al.
                          Wartolowska, K. A., Gerry, S., Feakins, B. G., Collins, G. S., Cook, J.,
Judge, A., & Carr, A. J. (2017). A meta-analysis of temporal changes of
response in the placebo arm of surgical randomized controlled trials: an
update. Trials, 18, [323]. https://doi.org/10.1186/s13063-017-2070-9
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s13063-017-2070-9
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMC Trials at
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2070-9. Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
UPDATE Open Access
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Abstract
Background: Temporal changes in the placebo arm of randomized controlled trials (RCTs) have not been
thoroughly investigated, despite the fact that results of RCTs depend on the comparison between arms.
Methods: In this update of our earlier systematic review and meta-analysis, we set out to investigate the effect of
assessment time and number of visits on the magnitude of change from baseline in the placebo arm of these trials.
We used linear mixed-effects models to account for within-trial correlations.
Results: Across all 47 trials the magnitude of response in the placebo arm did not change with time (β = -0.0070,
95% CI -0.024, 0.010) or visit (β = -0.033, 95% CI -0.082, 0.017) and remained significantly different from baseline for
at least 12 months or seven follow-up visits. Change in the placebo arm in trials with subjective outcomes was
large (β0 = 0.68, 95% CI 0.53, 0.82) and relatively constant across time (β = -0.0042, 95% CI -0.024, 0.016) and visit
(β = -0.029, 95% CI -0.089, 0.031), whereas in trials with objective outcomes the response was smaller (β0 = 0.28, 95% CI
0.11, 0.46) and diminished with time (β = -0.030, 95% CI -0.050, -0.010), but not with visit (β = -0.099, 95% CI -0.30, 0.11).
For trials with assessed outcomes, there was no significant effect of time (β = -0.0071, 95% CI -0.026, 0.011) or
visit (β = -0.032, 95% CI -0.33, 0.26); however, these results should be interpreted with caution due to the small
number of studies, and high clinical heterogeneity between studies. In trials with pain as an outcome,
the improvement was significant (β0 = 0.91, 95% CI 0.75, 1.07), but there was no effect of time (β = -0.013,
95% CI -0.06, 0.03) or visit (β = -0.045, 95% CI -0.16, 0.069), and pain ratings remained significantly different
from baseline for 12 months or seven visits.
Conclusions: These results are consistent with our previous findings. In trials with subjective outcomes
response in the placebo arm remains large and relatively constant for at least a year, which is interesting
considering that this is an effect of a single application of an invasive procedure. The lack of effect of time
and visit number on subjective outcomes raises further questions regarding whether the observed response is
the result of placebo effect or the result of bias.
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Background
There is conflicting evidence regarding the change in
magnitude of placebo response in randomized controlled
trials (RCTs). Several studies have demonstrated that
values in the placebo arm remain different from baseline
for the duration of the follow up [1–3]. However, there is
no consensus as to whether placebo response does [4–6]
or does not [4, 7] significantly change with time, and as
to whether placebo response has a time-effect curve with
a peak and carry-over effect [2, 8]. Experimental studies,
specifically designed to investigate temporal changes after
placebo administration, typically use a very short obser-
vation time, e.g., under an hour [9, 10], so their results
provide little insight into what happens in clinical trials,
in which the follow up lasts weeks or months.
In the previous paper [3], we used data from our
earlier systematic review of surgical RCTs with a pla-
cebo arm [11] to determine the effect of time on the
effect size of the primary outcome at the primary as-
sessment time point. [3] We observed that the effect
in the placebo arm remained significantly different
from baseline throughout blinded follow up, but that
the timing of the assessment did not appear to affect
the magnitude of effect.
Typically, meta-analyses focus on the effect size at
the primary assessment time point and treat it as a
single outcome measure of treatment efficacy; how-
ever, trials often report outcomes at multiple follow-
up visits. In this paper, we have assessed the temporal
characteristics of changes in the placebo arm using a
meta-analysis of within-and between-study changes
across all outcome time points for all analyzed surgi-
cal RCTs. Our aim was to verify the findings from
our earlier paper by incorporating the data from all
reported follow-up visits, accounting for within-study
and between-study correlations, and to investigate the
effect of the outcome type and number of visits on
temporal changes in the placebo arm of surgical
RCTs.
Methods
Search strategy, eligibility and data extraction
The details of the search strategy and data extraction have
been published previously [11]. In brief, we searched the
databases of MEDLINE, EMBASE, CENTRAL, and Clini-
calTrials.gov for placebo-controlled RCTs investigating
the efficacy of a surgical intervention. The databases were
searched from their inception to October 2015.
Surgical intervention was defined as “any interven-
tional procedure that changed the anatomy and required
a skin incision or the use of endoscopic techniques.
Dental studies and invasive procedures used to deliver a
pharmacological substance or stem cells, or that aimed
to alleviate symptoms by modulation, stimulation or
denervation were excluded”. Placebo was defined as
“sham surgery, or an imitation procedure intended to
mimic the active intervention; including the scenario
where a scope was inserted and nothing was done, but
patients were sedated or under general anesthesia and
could not distinguish whether or not they underwent
the actual surgery” [11].
We only included trials that reported continuous data
and presented data in a form that made it possible to
calculate an effect size. From each eligible study, we ex-
tracted the lead author’s surname, the publication year,
the number and timing of each treatment and follow-
up visit, the primary outcome, and the mean and stand-
ard deviation (SD) of the primary outcome in the pla-
cebo arm of each trial. Outcomes were classified as
“subjective”, i.e., patient-reported and depending on the
patients’ perceptions and cooperation, “assessed”, i.e.,
subjective ratings judged by external assessors or “ob-
jective”, i.e., measured using devices or laboratory tests
and independent of patients’ or observers’ perceptions,
for example, weight. As most of the literature on placebo
effect is related to pain studies, we also extracted data on
pain outcomes, irrespective of whether these were primary
or secondary outcomes, for a secondary analysis.
Study effect sizes were quantified as within-arm
standardized mean differences (SMDs) between baseline
and follow-up values using the Cohen’s d method [12].
A pretest-posttest correlation coefficient (r) of 0.5 was
used to calculate the standard error of each SMD [3].
Where necessary, SMDs were sign-flipped to ensure that
improvement was consistently presented as a reduction
in SMD.
Model for analysis of multiple time points
In order to analyze the trajectory of change in the
placebo arm, we adopted a similar method to that
proposed by Ishak et al. [13], who conducted a meta-
analysis of longitudinal studies reporting data at a series of
fixed time points, and then used linear mixed-effects
models to account for correlations, both within and be-
tween studies. We adapted Ishak’s method to conduct a
meta-analysis of studies that report data at many different
and irregularly spaced time points, while still accounting
for correlations between data points within and between
studies. All standardized data points from each individual
study were included. We used a random coefficients
model (also known as a random intercept and slope
model) with continuous time, which allows for an arith-
metic description of the relationship between the meas-
urement of interest and time from baseline [14]. The
models were based on polynomials of time by adding
higher-order polynomials, first as fixed effects, then as
random coefficients. Decisions on which terms to include
in the final model were based on Akaike information
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criteria. When assessing the benefit of additional fixed and
random effect terms, model parameters were estimated
using maximum likelihood. Restricted maximum likeli-
hood estimation was used when fitting the final model.
Each observation was weighted according to the inverse
variance of the study measures at each time point. To ac-
count for the within-study correlation of observations a
first-order continuous auto-regressive (CAR1) covariance
structure was used, which accounts for the irregular time
periods between measurements. In the scenario where ob-
servations are equally spaced, this is identical to a first-
order autoregressive (AR1) structure.
In analyzing the effect of the timing of all reported
follow-up visits on SMDs within the placebo arm of surgi-
cal RCTs, the intention was to look for changes that might
not have been present when only the primary assessment
time point was analyzed [3]. As the type of outcome has
been demonstrated to have an effect on the magnitude of
response in the placebo arm, we also investigated temporal
changes after subgrouping trials by outcome type [3, 15].
In this case, a separate model was fitted for each subgroup
(subjective, assessed and objective). We also performed
meta-analyses using visit number (instead of time from
baseline) as a fixed effect to investigate the effect of
repeated assessments. Finally, as most of the literature on
placebo is related to placebo analgesia, we analyzed
temporal changes only within trials in which pain was the
outcome. For the analysis of some subgroups (assessed
and objective outcomes) only a small number of stud-
ies were available, and model convergence was not
satisfactory; in these cases, a simpler random-intercept-
only model was fitted.
In all cases, a linear term for time was found to be suf-
ficient for both the fixed and random parts of the model;
that is, adding higher-order polynomial terms did not
improve the model fit. We chose to weight each obser-
vation by its inverse variance; however, removing this
weighting from the models did not change any of the
conclusions. Analyses were limited to 12-month follow
up and to seven follow-up visits due to the small num-
ber of trials with more visits and longer follow-up pe-
riods. All meta-analyses were performed using SAS
software version 9.4 (SAS Institute Inc., Cary, NC, USA)
using the “mixed” and “sgplot” procedures.
Results
Study selection and characteristics
Information on the search strategy, Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow diagram, and characteristics of the identi-
fied and included trials have been reported previously
[3], with an abridged version presented in Additional
file 1. A total of 47 trials, involving 1744 participants,
were eligible for inclusion. The median duration of
blinded follow up was 6 months, with an interquartile
range (IQR) of 3 − 12 months. The median number of
blinded visits was 1 (IQR 1 − 3).
Main findings
Across all analyzed surgical RCTs, the magnitude of pla-
cebo response did not diminish with time or visit, and
remained significantly different from baseline for the
duration of the trial (Fig. 1, Tables 1 and 2).
When trials were subdivided by outcome type, time
was associated with statistically significant decreases in
placebo response in trials with objective outcomes. For
trials with subjective outcomes, neither time nor visit
were significantly associated with change in placebo re-
sponse; however, the response remained large and sig-
nificantly different from baseline for at least 12 months.
Neither time nor visit were significantly associated with
the magnitude of placebo response in trials with assessed
outcomes, but few studies were included in this analysis
(Fig. 2, Tables 3 and 4).
In analyses limited to trials with pain as the outcome,
the effects of time and visit were not significant (Fig. 3,
Tables 5 and 6).
Discussion
Main findings
To the best of our knowledge, this is the first meta-
analysis modelling longitudinal changes in the magnitude
of effect in the placebo arm of surgical RCTs across all
follow-up visits. This study supports our earlier findings
that, across all analyzed trials, the magnitude of placebo
response does not significantly change with time; it also
shows that placebo response does not change with the
number of visits. However, when trials were subdivided by
outcome type, for trials with subjective outcomes, the re-
sponse in the placebo arm remained large and relatively
constant for at least 12 months or seven visits, while for
trials with objective outcomes, the improvement in the
placebo arm diminished with time but not with follow-up
visits. It should be noted that, unlike pharmaceutical trials,
in which there may be multiple applications of a placebo
regimen, all but three trials analyzed in this study used a
“one-off” placebo intervention (Additional file 1).
Strengths and limitations
The main strength of this paper is that, unlike our previous
analysis, we investigated the effect of time and visit number
across all follow-up visits. The main limitation of this study
is the paucity of data; both in the form of the number of eli-
gible studies, and the number of observations per study.
We were not able to investigate the extent to which
placebo response was caused by the so called “true
placebo effect”, i.e., the difference in effect between the
placebo and non-interventional arms [16], because only
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one trial included a non-intervention group [17]. Ana-
lyses were limited to the assessment of “placebo re-
sponse”, i.e., the total change in the placebo arm
between the baseline and follow-up visits. As a conse-
quence of this, the magnitude of response may be af-
fected by factors that are not related to placebo
intervention itself, such as regression to the mean, fluc-
tuations in disease severity, spontaneous improvement
or report bias.
Seventy-nine percent of the trials used or allowed the
use of standard or rescue medication [3]; therefore, some
of the effect observed in the placebo group may be the
result of concomitant pharmacological treatment or life-
style modifications. We did not include any information
about concomitant medication in our analysis because of
the limited reporting of this characteristic in the ana-
lyzed trials.
Analyses were based on summary data, as reported by
the authors of each trial. This limited the power of our
analyses and did not allow us to investigate the effect of
patient-related factors; therefore, we were unable to
draw inference about individual patient responses (sig-
nificant relationships at the population level may not
hold true at the individual level and vice versa, i.e., the
ecological fallacy).
The statistical modelling carried out in this study re-
lied on several choices and assumptions. We chose to
use SMDs for the outcome measure, as the reported out-
come types and measures were heterogeneous, rendering
standardization necessary to combine results. In a study
with baseline and multiple follow-up outcome assess-
ments, we would typically adjust for the magnitude of
the outcome at baseline, but this was not appropriate
here. There is also the possibility that the standard error
of each study estimate was not appropriately accounted
for, since the baseline value was incorporated in the
SMD and the weighting at each time point; however, re-
moving the weighting from the model made little differ-
ence to the findings.
Interpretation
This study confirms our previous findings that placebo
response does not seem to have a response-curve and that
it persists for at least 12 months [3].
The “longevity” of placebo response has been reported
previously [1, 2] and has been interpreted by some au-
thors as regression to the mean [18–20]. In this study,
we could not investigate whether placebo response was
caused by regression to the mean because of the lack of
information on the true population mean for the out-
come measures. However, regression to the mean could
explain many of the characteristics of placebo response,
for example, that it tends to be larger for more extreme
values and for more unreliable measures. [20].
Table 2 The effect of visit on placebo response across all trials
Outcome
type
Intercept Coefficient
β0 (95% CI) P value β (95% CI) P value
All 0.56 (0.42, 0.71) <0.0001 -0.033 (-0.082, 0.017) 0.16
Table 1 The effect of time (in months) on placebo response
across all trials
Outcome
type
Intercept Coefficient
β0 (95% CI) P value β (95% CI) P value
All 0.55 (0.42, 0.68) <0.0001 -0.0070 (-0.024, 0.010) 0.40
Fig. 1 Meta-analysis of placebo response across all trials. Left panel shows analysis across all time points. Right panel shows analysis across all
visits. The thick line refers to the study average trend over time, i.e., the fixed effects part of the model. The shaded area is the 95% confidence
interval. The thick grey dashed line represents the line of null effect
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Using longitudinal analysis showed that outcome type
affects not only the magnitude of response in the pla-
cebo arm, but also its temporal changes; with the effect
on objective outcomes decreasing with time, and the ef-
fect on subjective outcomes, including pain, not chan-
ging with time and remaining significantly different from
baseline values. This is in line with the results of our ori-
ginal paper [3]. Findings in previously published studies,
investigating temporal changes in the placebo arm have
been inconsistent. Some studies reported that the effect
of time is not significant [4] or that trial duration may
explain some of the variation in improvement [21]. A
meta-analysis of acupuncture trials [2], showed a peak in
placebo response at 12 weeks with a subsequent drop at
52 weeks; however, the follow-up visits were divided into
six groups according to the assessment timing, allowing
a different number of trials to contribute to the effect in
each group. Kaptchuk et al. [5] reported a continuous
reduction in pain over 8 weeks in a sham acupuncture
trial; however, they re-applied the treatment throughout
Table 3 The effect of time (in months) on placebo response
across all trials, by outcome type
Outcome
type
Intercept Coefficient
β0 (95% CI) P value β (95% CI) P value
Subjective 0.68 (0.53, 0.82) <0.0001 -0.0042 (-0.024, 0.016) 0.67
Assessed 0.37 (-0.070, 0.81) 0.086 -0.0071 (-0.026, 0.011) 0.38
Objective 0.28(0.11, 0.46) 0.0037 -0.030 (-0.050, -0.010) 0.0084
Table 4 The effect of visit on placebo response across all trials,
by outcome type
Outcome
type
Intercept Coefficient
β0 (95% CI) P value β (95% CI) P value
Subjective 0.67 (0.50, 0.83) <0.0001 -0.029 (-0.089, 0.031) 0.28
Assessed 0.36 (-0.079, 0.80) 0.091 -0.032 (-0.33, 0.26) 0.51
Objective 0.32 (0.15, 0.50) 0.0024 -0.099 (-0.30, 0.11) 0.10
Fig. 2 Meta-analysis of placebo response across all the trials, by outcome type. Top panels shows data for individual trials. Bottom panels shows
meta-analysis by trial type. Left panels show analysis across all time points. Right panels show analysis across all visits. A separate model was fitted
for each outcome type. The thick line refers to the study average trend over time, i.e., the fixed effect part of the models. The shaded area is the
95% confidence interval. The thick grey dashed line represents the line of null effect
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the study, and it is known that administering treatment
multiple times reinforces the placebo effect [22].
In our meta-analysis, visit number did not have a sig-
nificant effect on the magnitude of placebo response.
This contradicts the findings of Vase et al., who reported
that a larger number of face-to-face visits was associated
with a larger placebo response [23]. However, Vase et al.
used individual patient data from several pharmaco-
logical trials, in which a placebo was administered
multiple times during the trial, whereas we analyzed
trial-level data from surgical trials, which tend to involve
a “one-off” intervention.
Some of the improvement in the placebo arm might
have been related to the effect of concomitant treatment.
One plausible explanation for improvement is the use of
rescue medications, such as pain-killers, or the introduc-
tion of lifestyle modifications, such as diet. Another pos-
sible explanation is that patients who were allowed to
continue their standard pharmacological treatments
throughout the trial might have improved due to better
adherence to these treatments when in the trial.
Implications
There are two main implications of this study. First, for the
researchers and clinicians designing placebo-controlled tri-
als of invasive procedures using subjective outcomes, it is
useful to know that the effect in the placebo arm does not
seem to change significantly with time. This is important
because in a placebo-controlled trial treatment effect
is measured as the difference between the change in
the active and placebo arms. Second, patients report
significant improvement for a prolonged period of
time after a single surgical placebo intervention, i.e., a
procedure chosen to have no active therapeutic effect.
Therefore, surgeons and therapists should be aware
that large and sustained improvement in subjective
outcomes after a procedure does not always mean
that the crucial surgical element of the treatment is
effective.
Conclusions
This study found that for surgical RCTs with subjective
outcomes, the effect size in the placebo arm persists
for at least a year, and does not significantly diminish
with follow-up visits. Only in trials with objective out-
comes did the magnitude of placebo response diminish
with time, but not with number of visits. These find-
ings further reinforce the value of controlling for
potential bias, especially in trials with a subjective key
outcome. Further research is needed to explore the
extent to which the observed response in the placebo
arm is explained by response bias and other potential
sources of bias.
Fig. 3 Meta-analysis of placebo response in trials with pain as the primary outcome. Left panel shows analysis across all time points. Right panel
shows analysis across all visits. The thick line refers to the study average trend over time, i.e., the fixed effects part of the model. The shaded area
is the 95% confidence interval. The thick grey dashed line represents the line of null effect
Table 5 The effect of time (in months) on placebo response in
trials with pain as the outcome
Outcome Intercept Coefficient
β0 (95% CI) P value β (95% CI) P value
Pain 0.91 (0.75, 1.07) <0.0001 -0.013 (-0.06, 0.03) 0.48
Table 6 The effect of visit on placebo response in trials with
pain as the outcome
Outcome Intercept Coefficient
β0 (95% CI) P value β (95% CI) P value
Pain 0.94 (0.72, 1.15) <0.0001 -0.045 (-0.16, 0.069) 0.36
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Additional file
Additional file 1: Characteristics of surgical randomized controlled trials
with a placebo arm included in this analysis. (PDF 47 kb)
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